DBV Technologies completes P II study of milk-induced EoE treatment

DBV Technologies has completed a SMILEE trial – Phase IIA investigator-initiated clinical trial of Viaskin Milk for the treatment of milk-induced Eosinophilic Esophagitis (EoE) in children ages 4-17 has been completed.  

The results of the study are expected in the first half of 2018.

Dr. Antonella Cianferoni, Assistant Professor of Pediatrics at Children`s Hospital of Philadelphia (CHOP) and Principal Investigator of SMILEE explined that EoE is a progressive and chronic inflammatory disease that can be debilitating and painful for patients. Over the last decade, EoE has increased in incidence in the United States, but no FDA approved therapies are available for patients today. If left untreated, EoE may cause permanent and significant damage to the esophagus and gastrointestinal track.

The SMILEE trial is being conducted under an Investigational New Drug (IND) application held by Dr. Jonathan Spergel at Children`s Hospital of Philadelphia (CHOP).